【摘要】 目的:观察甘精胰岛素、那格列奈、罗格列酮联合用药治疗磺脲类药物继发失效(SFS)的2型糖尿病(T2DM)患者的血糖(PG)控制和胰岛β细胞功能恢复情况。方法:选择38例用磺脲(SU)类药物继发失效的2型糖尿病患者,改用甘精胰岛素、那格列奈、罗格列酮联合治疗3个月,采用自身前后对照观察空腹血糖(FPG),餐后2小时血糖(2hPG),餐后最高血糖(PPG),24小时血糖达标时间段,空腹基础C肽值(F-CP)和餐后C肽值(P-CP),糖化血红蛋白(HbA1C)变化。结果:血糖控制理想,胰岛β细胞功能改善有统计学意义(P<0.05)。结论:甘精胰岛素、那格列奈和罗格列酮联合治疗能有效控制磺脲类药物继发失效的2型糖尿病患者的血糖,并改善胰岛β细胞功能。更多还原

【Abstract】 Objective:To observe the clinical effects of combination of glargine insulin, nateglinide and rosiglitazone in type 2 diabetes(T2DM)patients with secondary failure of sulphonylureas(SFS). Methods:A total of 38 T2DM patients with secondary failure of sulphonylureas recieved glargine insulin,nateglinide and rosiglitazone.To cross-refer the treatment,many measurements were taken,which included fasting plasma glucose(FPG),two-hour postprandial plasma glucose(2hPG),postprandial plasma glucose(PPG),fasting C-peptide(F-CP),postprandial C-peptide(P-CP), hemoglobin A1C(HbA1C).Results:Triple therapy could improve the function of pancreatic β cell controlling the plasma glucose(P<0.05).Conclusion:Triple therapy of glargine insulin,nateglinide and rosiglitazone can effectively control the plasma glucose and improve the function of pancreatic β cell of islet in T2DM patients with SFS.更多还原